Effectiveness of PEA Compared to Placebo on Acute Menstrual Pain

Last updated: November 12, 2024
Sponsor: RDC Clinical Pty Ltd
Overall Status: Completed

Phase

4

Condition

Female Hormonal Deficiencies/abnormalities

Premenstrual Syndrome

Dysmenorrhea (Painful Periods)

Treatment

Microcrystalline cellulose

Levagen+

Clinical Study ID

NCT05810116
PEAMPS-23
  • Ages > 18
  • Female

Study Summary

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Palmitoylethanolamide (PEA) compared to placebo on menstrual pain in otherwise healthy participants 18 years and over.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women who experience mild to moderate menstruating pain

  • Aged 18 years or over

  • History of over the counter (OTC) analgesic use for the treatment of menstrual pain

  • Self-reported history of menstrual cramp pain occurring during four of the past sixmenstrual cycles.

  • Typically requires at least one dose of an OTC analgesic medication such asnaproxen, aspirin, ibuprofen or acetaminophen taken on at least 1 day of menstrualcycle for the treatment of mild to moderate menstrual cramp, and normallyexperiences pain relief from these medications.

  • Otherwise healthy

  • Able to provide informed consent

  • Regular menstrual cycle (28 days ± 7 days) and period

  • Agree not to participate in any other clinical trial while enrolled in this trial

Exclusion

Exclusion Criteria:

  • Secondary cause for dysmenorrhea (i.e. endometriosis, adenomyosis, uterine fibroidsor infection)

  • Any bleeding disorders, recent surgery or concurrent blood thinning treatment

  • Unstable or serious illness (e.g., kidney, liver, GIT, heart conditions, diabetes,thyroid gland function, lung conditions, chronic asthma, diagnosed psychological ormood disorder) (1)

  • Current malignancy (excluding BCC) or chemotherapy or radiotherapy treatment formalignancy within the previous 2 years

  • Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or otheranticoagulation therapy

  • Pregnant or lactating women

  • Active smokers, nicotine use or drug (prescription or illegal substances) abuse

  • Chronic past and/or current alcohol use (>14 alcoholic drinks week)

  • Allergic or hypersensitive to any of the ingredients in active or placebo formula

  • Any condition which in the opinion of the investigator makes the participantunsuitable for inclusion

  • Participated in any other clinical trial during the past 1 month

  1. An unstable illness is any illness that is currently not being treated with astable dose of medication or is fluctuating in severity. A serious illness is acondition that carries a risk of mortality, negatively impacts quality of lifeand daily function and/or is burdensome in symptoms and/or treatments.

Study Design

Total Participants: 80
Treatment Group(s): 2
Primary Treatment: Microcrystalline cellulose
Phase: 4
Study Start date:
May 19, 2023
Estimated Completion Date:
December 20, 2023

Connect with a study center

  • RDC Clinical Pty Ltd

    New Farm, Queensland 4006
    Australia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.